# Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

> **NCT02398188** · PHASE3 · COMPLETED · sponsor: **Evofem Inc.** · enrollment: 793 (actual)

## Conditions studied

- Central Abdominal Bulging

## Interventions

- **DRUG:** LIPO-202
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02398188
- **Lead sponsor:** Evofem Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-09
- **Primary completion:** 2015-10-29
- **Final completion:** 2015-10-29
- **Target enrollment:** 793 (ACTUAL)
- **Last updated:** 2019-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02398188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02398188, "Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02398188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*